Introduction
============

Carpal tunnel syndrome (CTS) or compressive neuropathy of the median nerve under the flexor retinaculum of the wrist is the most common entrapment neuropathy.[@b1-jpr-12-579] The incidence of CTS has been reported to be 6.7%--7.8%.[@b2-jpr-12-579]--[@b4-jpr-12-579] Currently, there is no consensus about the appropriate treatment of CTS at different stages of the condition.[@b5-jpr-12-579] In general, the surgical release of the flexor retinaculum is recommended to be done when the disease is advanced with severe symptoms or atrophy in physical examination.[@b6-jpr-12-579] Nonoperative treatments should be considered in mild to moderate cases.[@b7-jpr-12-579]--[@b12-jpr-12-579]

Previously, only few studies have compared the efficacy of local injection of different substances in patients with CTS.[@b13-jpr-12-579]--[@b18-jpr-12-579] Corticosteroids, especially methylprednisolone and triamcinolone, are among the most prevalent medications used for local injection in patients with CTS.[@b13-jpr-12-579]--[@b15-jpr-12-579] The therapeutic mechanism of local corticosteroid injection (CSI) has been speculated via a probable suppression of inflammation and a subsequent decompression of the median nerve. CSI is well established and the most rapid injection with a documented short-term efficacy, but there is inadequate evidence over the best choice of steroid and dose.[@b8-jpr-12-579],[@b19-jpr-12-579]--[@b21-jpr-12-579] Evidently, the complications of local corticosteroids should be cautiously considered, in particular regarding diabetic patients.[@b20-jpr-12-579]

Regarding the extensive variety of treatments, as well as their combinations, and due to the lack of comprehensive meta-analyses in view of different study designs and various patient characteristics, the most efficient steroid and its most appropriate dosage that would be associated with best outcomes and less complications remain controversial. In the current randomized controlled trial (RCT), the efficacy and safety of local injection of methylprednisolone and triamcinolone at two different doses of 20 and 40 mg were compared within a follow-up period of 3 months, in patients with mild to moderate CTS.

Patients and methods
====================

During the first 6 months of 2017 from January to June, 112 patients referred to the Electrodiagnosis Unit of Shohada-e-Tajrish Hospital with complaints related to one of the main symptoms of CTS were consecutively recruited. Sampling continued until 80 electrodiagnostically confirmed CTS cases of mild or moderate stages were included. A written informed consent was obtained from all the eligible patients in compliance with the Declaration of Helsinki. Then, they were assigned to four groups of 20 members each using block randomization method (block size =4 members): 20 mg triamcinolone (T20), 40 mg triamcinolone (T40), 20 mg methylprednisolone (M20), and 40 mg methylprednisolone (M40).

All the included patients were symptomatic, as they had at least one of the major symptoms of CTS (pain, numbness, paresthesia in the palm or fingers, and subjective weakness in grip). The symptoms should have been lasting for 3--12 months and not been relieved by other conservative treatments such as night splinting and physical agent modalities such as laser therapy, ultrasonography (US), and manual therapy.[@b22-jpr-12-579] The exclusion criteria were severe stage of CTS; current pregnancy; any history of diabetes mellitus, rheumatoid arthritis, or thyroid disorders; previous history of relevant surgery or hand trauma; any local injection in wrist within the last 6 months; thenar atrophy in physical examination; and active cervical radiculopathy or other peripheral neuropathies in the upper extremity.

In the case of bilateral involvement, only the side with more severity was included.

Furthermore, if electrodiagnostic studies did not confirm the presence of CTS, the patient was excluded. The patients and also the physicians who were responsible for injection and evaluation (electrodiagnostic and clinical measurements) were all blinded to the groups. The syringes were covered by aluminum envelopes to hide the materials. The Institutional Review Board and Ethics Committee of Shahid Beheshti University of Medical Sciences approved the study protocol (Number: IR.SBMU.MSP.REC.1396.157). We also registered this trial in the Iranian Registry of Clinical Trials (ID number: IRCT20130523013442N22).

The demographic characteristics of the patients such as age, gender, height, weight, body mass index (BMI), and the severity grade of disease were recorded. The clinical outcome--measuring tools were as follows: 1) a 10-score VAS in which 0 indicated "no pain" while 10 indicated the "maximal imaginable pain", which was used to assess the pain intensity; 2) Boston Carpal Tunnel Syndrome Questionnaire (BCTQ), which had two sections: symptom severity scale (SSS) of eleven items and functional status scale (FSS) of eight items. Each of these 19 questions had five choices based on the severity of involvement; higher scores indicated more severity of the condition; 3) pain-free grip strength (PFGS) utilizing dynamometer per kilogram; and 4) electro-diagnostic studies of median nerve measuring the amplitude (= amp) and latency of compound motor action potential (CMAP), latency of sensory nerve action potential (SNAP), and nerve conduction velocity (NCV) for motor fibers. In the electrodiagnostic evaluation, the criteria for the diagnosis of "mild" CTS were SNAP latency \>3.6 ms with preserved SNAP amp, normal CMAP amp, and latency, while criteria for the diagnosis of "moderate" CTS were SNAP latency \>3.6 ms in addition to CMAP latency of between 4.2 and 6.5 ms, with a preservation of SNAP.[@b23-jpr-12-579] The first two variables (VAS and BCTQ) were our primary outcome-measuring tools, but PFGS and electrodiagnostic parameters were also evaluated as the secondary outcomes.

The local steroid injection was performed using the assigned substance for each group by the same physiatrist with a 20 years of expertise in the field of neuromuscular injections (the first author), under sterile condition, via landmark-guided method and without the guidance of US. The patients were lying supine while the wrist was placed on a table in resting position with slight wrist dorsiflexion. A 25-G needle was inserted in the volar surface of the wrist, above the distal wrist crease, between the two tendons of *palmaris longus* and *flexor carpi radialis*. After skin preparation, based on the conventional midline approach for CTS, injection was performed by passing the needle through the flexor retinaculum into the carpal tunnel. If the aspiration was negative, 1 mL of the drug was administered in combination with 1 mL of 2% lidocaine. After injection, all the patients remained in the clinic for at least half an hour to observe any severe reactions. They were advised to apply some lifestyle modifications (avoiding repetitive fine hand movements, lifting heavy objects, or prolonged flexed wrist position) and use acetaminophen per need, only within the next 48 hours. A senior physical medicine resident (the fourth author, SB) was responsible for having a phone call with the patients 3 and 10 days after injection. The patients were also asked to attend clinical and electrodiagnostic reassessment in the clinic after 3 months, in which the preinjection measurements (VAS for pain, PFGS, two parts of BCTQ, and electrodiagnostic parameters) were taken repeatedly. Data analysis was performed using SPSS statistical software Version 22.0. One-way ANOVA and Tukey's honest significant difference test were used to compare the quantitative variables between the four groups. To compare the pre- and posttreatment variables in each group, Wilcoxon test or paired *t*-test was used. The significance level was considered at *P*\<0.05.

Results
=======

Among the 80 eligible participants, 7 patients did not return to the last visit due to personal problems or other reasons, none of which were related to our injections or complications. Therefore, the study was completed with 73 patients: 18, 20, 17, and 18 patients in T20, T40, M20, and M40 groups, respectively. Initially, the four groups were relatively similar in terms of age, gender, BMI, and the severity grade of the condition ([Table 1](#t1-jpr-12-579){ref-type="table"}). As can be observed in [Table 2](#t2-jpr-12-579){ref-type="table"}, between the two parts of BCTQ (SSS and FSS), SSS significantly decreased in all the groups after the injection, without any significant difference between them. The other score (FSS) also significantly decreased in the four groups; however, the improvement was significantly higher in T40 group compared with T20 group (Tukey's *P*=0.009).

In [Table 3](#t3-jpr-12-579){ref-type="table"}, all electrodiagnostic parameters including SNAP latency, CMAP amp or latency, and NCV are compared in each group (pre- and posttreatment values) and among the four groups, using paired *t*-test and one-way ANOVA, respectively.

SNAP "latency" improved in all the groups after the treatment; there was no significant difference among them in their improvement. Similarly, CMAP latency and subsequently NCV values decreased significantly in all the groups at a follow-up period of 3 months, and no significant difference among them was found. On the other hand, CMAP amp improved significantly only in T40 group (*P*=0.032), while there was no significant improvement in the other groups.

Among other nonelectrodiagnostic variables ([Table 2](#t2-jpr-12-579){ref-type="table"}), PFGS improved significantly in all the groups, except for M20. Similar improvements were found regarding the pain intensity (VAS) in all the four groups. Furthermore, throughout combining the relative groups, we reclassified data into two larger groups of 20 mg vs 40 mg injections to achieve a more valid analysis. Among all the variables, only FSS showed a remarkable superiority in favor of 40-mg group. In a similar way, we compared two cumulative groups of triamcinolone vs methylprednisolone, with 38 and 35 members, respectively. However, none of the two substances demonstrated any significant superiority ([Table 4](#t4-jpr-12-579){ref-type="table"}). Eventually it is noteworthy that this study had neither minor nor major complications related to local steroid injection.

Discussion
==========

CSI, an established therapeutic method, due to the rapid effects and safety, is usually considered before surgery, for patients with nonsevere CTS, particularly in whom the other conservative therapies did not relieve the symptoms.[@b8-jpr-12-579],[@b24-jpr-12-579],[@b25-jpr-12-579] The better outcomes with local steroid injection in comparison with placebo, oral medications or splinting have been proven in several studies spanning over the three decades.[@b26-jpr-12-579],[@b27-jpr-12-579] However, the type of corticosteroid and its appropriate dosage remain controversial.

Some authors have compared the efficacy and safety of popular corticosteroids at different dosages in CTS patients.[@b13-jpr-12-579]--[@b15-jpr-12-579] O'Gradaigh and Merry compared the outcomes of local injection of long- and short-acting corticosteroids at different dosages. After 6 weeks and also 6 months, the efficacy of administrating 25 mg hydrocortisone was comparable to that of 100 mg hydrocortisone or 20 mg triamcinolone. Therefore, the authors suggested lower dosage of corticosteroid, regarding potentially lower toxicity. However, their study had some shortcomings such as using overall lower doses in comparison with other trials, lack of power to detect significant differences, and employing a very complex design.[@b15-jpr-12-579]

Recently, Salman Roghani et al compared the effectiveness of local injections of 40 and 80 mg triamcinolone in a 3 mL solution of lidocaine and normal saline (NS) among CTS patients in Iran. In the control group, only 1 mL of 2% lidocaine and 2 mL of NS were administered. The authors found no remarkably significant difference between the two groups; then, they concluded that hydrodissection is more important than anti-inflammatory effects of corticosteroids.[@b13-jpr-12-579] However, because of lidocaine injection in all the groups and other nonspecific benefits of participants for being in an RCT, this effect might not be so "pure", as the authors have said.

In another trial in the Netherlands, Dammers et al locally injected 20, 40, and 60 mg hydrocortisone for patients with CTS. Eventually no significant difference was found between the groups after 12-month follow-up; however, after 6 months, the symptoms were relieved in 56%, 53%, and 73% of patients of 20-, 40-, and 60-mg groups, respectively.[@b14-jpr-12-579] this study, it was demonstrated that local CSI led to pain relief, improved SSS and FSS scores, increased grip, and improved electrophysiologic parameters (SNAP, CMAP, and NCV). Because of some limitations in our trial such as limited sample size and short-term follow-up, only small differences between the investigated groups were found, which should be cautiously considered. Local injection of 20 mg methyl-prednisolone did not affect PFGS, while PFGS significantly increased in the other three groups. In addition, there were some findings in favor of better outcomes in groups with an injection of 40 mg corticosteroids; 1) FSS was significantly better in 40-mg group compared with 20 mg injection of both substances, especially triamcinolone, after 3-month follow-up (*P*=0.005), and 2) CMAP amp improved significantly only in T40 group (*P*=0.032), while there was no significant improvement in the other groups. It is noteworthy that, in the present study, there were no complications related to local steroid injection and lack of a control group.

Conclusion
==========

Based on the findings of the current study, local injection of long-acting and short-acting corticosteroids at different dosages can result in a substantial improvement in functional status and symptom relief in patients with CTS in short-term follow-up. However, higher dosage of both substances, especially triamcinolone, was associated with better outcomes in functional status.
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###### 

Comparison of demographic characteristics and baseline variables among the patients of the four groups

                  M40 (n=18)   T40 (n=20)   M20 (n=17)   T20 (n=18)   *P*-value   
  --------------- ------------ ------------ ------------ ------------ ----------- -------
  Age (years)     56±8.5       54.8±7.6     52.3±8.8     57.8±6.6     0.236       
  BMI (kg/m^2^)   28.14±3.4    26.4±2.7     25.6±2       27.7±4       0.132       
  Gender          Male         5            6            5            7           0.291
  Female          13           14           12           11                       
  CTS severity    Mild         6            7            5            7           0.197
  Moderate        12           13           12           11                       

**Abbreviations:** BMI, body mass index; CTS, carpal tunnel syndrome; M20, 20 mg methylprednisolone; M40, 40 mg methylprednisolone; T20, 20 mg triamcinolone; T40, 40 mg triamcinolone.

###### 

Comparison of pre- and posttreatment clinical values in each group and between groups

                                   Pre         Post                                               *P*-value (paired *t*-test)
  -------------------------------- ----------- -------------------------------------------------- --------------------------------------------------
  **PFGS (kg)**                                                                                   
  T20 (n=18)                       25.1±8.5    30.6±10.9                                          0.007[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  T40 (n=20)                       28.9±12.8   33.1±14.4                                          0.001[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  M20 (n=17)                       29.3±10.5   35.7±19.8                                          0.061
  M40 (n=18)                       24.6±10.7   29.4±11.9                                          0.001[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  *P*-value (ANOVA)                0.421       0.369                                              
  **VAS for pain (0--10 scale)**                                                                  
  T20 (n=18)                       5.4±2.4     4±1.8                                              0.007[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  T40 (n=20)                       5.4±2.4     3.7±2.2                                            0.001[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  M20 (n=17)                       5.6±1.8     4.1±1.9                                            0.014[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  M40 (n=18)                       5.3±2.9     3±2.2                                              0.006[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  *P* (ANOVA)                      0.975       0.474                                              
  **SSS (11--55 scale)**                                                                          
  T20 (n=18)                       32.5±11.8   24.9±10.2                                          0.002[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  T40 (n=20)                       31.7±8.6    22.3±11.1                                          0.001[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  M20 (n=17)                       31.9±8      22.8±8.5                                           0.001[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  M40 (n=18)                       32.2±9.3    22.6±7                                             0.001[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  *P* (ANOVA)                      0.995       0.878                                              
  **FSS (8--40 scale)**                                                                           
  T20 (n=18)                       22.6±9.9    17.1±6.9                                           0.001[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  T40 (n=20)                       21.8±7.3    11.3±2.8                                           0.001[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  M20 (n=17)                       19.2±6.5    15.8±4.5                                           0.001[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  M40 (n=18)                       23.2±9.6    15±5.9                                             0.002[\*](#tfn2-jpr-12-579){ref-type="table-fn"}
  *P* (ANOVA)                      0.528       0.011[\*](#tfn2-jpr-12-579){ref-type="table-fn"}   

**Note:**

indicates significant *P*-value.

**Abbreviations:** FSS, functional status scale; M20, 20 mg methylprednisolone; M40, 40 mg methylprednisolone; PFGS, pain-free grip strength; T20, 20 mg triamcinolone; T40, 40 mg triamcinolone; SSS, symptom severity scale.

###### 

Comparison of pre- and posttreatment electrodiagnostic values in each group and between groups

                            Pre        Post       *P*-value (paired *t*-test)
  ------------------------- ---------- ---------- --------------------------------------------------
  **SNAP latency (ms)**                           
  T20 (n=18)                4.4±0.6    4.2±0.4    0.001[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  T40 (n=20)                4.4±0.8    4±0.6      0.001[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  M20 (n=17)                4.2±0.4    4±0.3      0.004[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  M40 (n=18)                4.7±0.9    4.4±0.7    0.003[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  *P* (ANOVA)               0.185      0.108      
  **CMAP latency (ms)**                           
  T20 (n=18)                4.3±0.6    4.2±0.7    0.001[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  T40 (n=20)                4.5±0.8    4±0.6      0.001[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  M20 (n=17)                4.5±0.8    4±0.5      0.006[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  M40 (n=18)                4.7±0.9    4.4±0.8    0.001[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  *P* (ANOVA)               0.685      0.366      
  **CMAP amplitude (mV)**                         
  T20 (n=18)                5.8±1      6.3±1.4    0.117
  T40 (n=20)                6±1        6.6±1.3    0.032[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  M20 (n=17)                6.5±1.3    7±1.8      0.289
  M40 (n=18)                5.9±1      6.2±0.8    0.127
  *P* (ANOVA)               0.215      0.316      
  **Motor NCV (m/s)**                             
  T20 (n=18)                53.7±5.7   56.3±7.1   0.025[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  T40 (n=20)                51.6±5.6   54.4±5.9   0.001[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  M20 (n=17)                54.3±4.3   56.5±4.3   0.016[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  M40 (n=18)                51.3±4.5   54.0±5.6   0.001[\*](#tfn4-jpr-12-579){ref-type="table-fn"}
  *P* (ANOVA)               0.203      0.484      

**Note:**

indicates significant *P*-value.

**Abbreviations:** CMAP, compound motor action potential; M20, 20 mg methylprednisolone; M40, 40 mg methylprednisolone; NCV, nerve conduction velocity; T20, 20 mg triamcinolone; T40, 40 mg triamcinolone; SNAP, sensory nerve action potential.

###### 

Comparison of posttreatment values of clinical variables between cumulative groups

                           Post         *P*-value (Student's *t*-test)
  ------------------------ ------------ --------------------------------------------------
  **PFGS (kg)**                         
  T (n=38)                 31.9±12.1    0.80
  M (n=35)                 32.4±15.3    
  20 mg (n=35)             33.07±15.7   0.63
  40 mg (n=38)             31.34±13.2   
  **VAS (0--10 scale)**                 
  T (n=38)                 3.84±2.1     0.53
  M (n=35)                 3.53±2.1     
  20 mg (n=35)             4.05±1.8     0.14
  40 mg (n=38)             3.36±2.2     
  **SSS (11--55 scale)**                
  T (n=38)                 23.5±10.5    0.67
  M (n=35)                 22.6±7.7     
  20 mg (n=35)             23.88±9.3    0.50
  40 mg (n=38)             22.44±9.1    
  **FSS (8--40 scale)**                 
  T (n=38)                 14.0±4.9     0.27
  M (n=35)                 15.3±5.3     
  20 mg (n=35)             16.46±5.7    0.005[\*](#tfn6-jpr-12-579){ref-type="table-fn"}
  40 mg (n=38)             13.05±4.4    

**Note:**

indicates significant *P*-value.

**Abbreviations:** FSS, functional status scale; M, methylprednisolone; PFGS, pain-free grip strength; SSS, symptom severity scale; T, triamcinolone.
